For-Robin, Inc.

We are getting closer to our FDA application.

Our latest paper has just been published! We are on our way to the clinic. cGMP production has almost been completed and safety testing is underway. We should be in the clinic in a year!v.

Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models The Thomsen-Friedenreich antigen (TF-Ag-α) is found on ~85% of human carcinomas but is cryptic on normal tissue. The humanized highly specific hJAA-F11-H2aL2a and -H3L3 antibodies target TF-Ag-α without binding to TF-Ag-beta (found on ...

Japanese patent approved.

Chinese patent issued!

Driven by Personal Loss, Researcher Embarks On A Quest For a Better Breast Cancer Treatment Research at SUNY sees many outcomes that provide huge benefits to society, especially in health care. Breast cancer is one area of health care that is advancing, thanks to the quality research taking place around it. Academics and scientists across the SUNY system have long been at work finding all